These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 2472198

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A.
    Cancer Res; 1995 Feb 15; 55(4):840-6. PubMed ID: 7531616
    [Abstract] [Full Text] [Related]

  • 3. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
    Vuist WM, van Buitenen F, Hekman A, Melief CJ.
    Cancer Res; 1990 Sep 15; 50(18):5767-72. PubMed ID: 1697500
    [Abstract] [Full Text] [Related]

  • 4. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A.
    Cancer Res; 1995 Jun 15; 55(12):2627-34. PubMed ID: 7540106
    [Abstract] [Full Text] [Related]

  • 5. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
    Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R.
    J Immunol; 1986 Feb 01; 136(3):1123-30. PubMed ID: 3484499
    [Abstract] [Full Text] [Related]

  • 9. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins.
    van Oosterhout YV, van den Herik-Oudijk IE, Wessels HM, de Witte T, van de Winkel JG, Preijers FW.
    Cancer Res; 1994 Jul 01; 54(13):3527-32. PubMed ID: 7516821
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation.
    Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, Little M.
    Cancer Res; 2000 Aug 15; 60(16):4336-41. PubMed ID: 10969772
    [Abstract] [Full Text] [Related]

  • 14. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, Desjarlais JR, Zhukovsky EA.
    Cancer Res; 2008 Oct 01; 68(19):8049-57. PubMed ID: 18829563
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR, Klarnet JP, Peace DJ, Cheever MA, Badger CC, Bernstein ID, Greenberg PD.
    Cancer Res; 1990 Sep 01; 50(17):5421-5. PubMed ID: 2386946
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model.
    Velders MP, van Rhijn CM, Briaire IH, Fleuren GJ, Warnaar SO, Litvinov SV.
    Cancer Res; 1995 Oct 01; 55(19):4398-403. PubMed ID: 7671252
    [Abstract] [Full Text] [Related]

  • 17. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate.
    LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, Epstein AL.
    Cancer Res; 1991 May 15; 51(10):2694-8. PubMed ID: 2021947
    [Abstract] [Full Text] [Related]

  • 18. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H.
    Clin Cancer Res; 2005 May 15; 11(10):3879-88. PubMed ID: 15897589
    [Abstract] [Full Text] [Related]

  • 19. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2.
    Epstein AL, Khawli LA, Hornick JL, Taylor CR.
    Cancer Res; 1995 Jun 15; 55(12):2673-80. PubMed ID: 7780984
    [Abstract] [Full Text] [Related]

  • 20. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
    Gill I, Agah R, Hu E, Mazumder A.
    Cancer Res; 1989 Oct 01; 49(19):5377-9. PubMed ID: 2788499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.